Cargando…
Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)
BACKGROUND: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common treatments used among specialists and assess their interest in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604775/ https://www.ncbi.nlm.nih.gov/pubmed/26462481 http://dx.doi.org/10.1186/s12886-015-0122-z |
_version_ | 1782395104399458304 |
---|---|
author | Sy, Aileen O’Brien, Kieran S. Liu, Margaret P. Cuddapah, Puja A. Acharya, Nisha R. Lietman, Thomas M. Rose-Nussbaumer, Jennifer |
author_facet | Sy, Aileen O’Brien, Kieran S. Liu, Margaret P. Cuddapah, Puja A. Acharya, Nisha R. Lietman, Thomas M. Rose-Nussbaumer, Jennifer |
author_sort | Sy, Aileen |
collection | PubMed |
description | BACKGROUND: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common treatments used among specialists and assess their interest in newer therapies. METHODS: An international survey was distributed to dry eye researchers and expert practitioners via an internet survey. The survey data collected were analyzed with descriptive statistics. RESULTS: One hundred and fifteen respondents completed the survey; of these, 66 % were cornea specialists. The most commonly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluorometholone (FML) 0.1 % (59/99, 60 %), loteprednol etabonate 0.5 % (50/99, 51 %), and autologous serum eye drops (ASD; 48/97, 49 %). The most commonly prescribed non-topical medications included essential fatty acid supplements (72/104, 69 %), low-dose doxycycline (oral; 61/100, 61 %), and flaxseed supplements (32/96, 33 %) as well as punctal plugs (76/102, 75 %). Respondents reported treatment with topical corticosteroids for 2 to 8 weeks (46/86, 53 %), followed by less than 2 weeks (24/86, 28 %) and with topical CSA between 2 to 8 weeks (45/85, 53 %) followed by 2 to 6 months (24/85, 28 %). The top three signs and symptoms reported to indicate treatment response were, in order, fluorescein staining of the cornea, reduction in foreign body sensation, and reduction in burning sensation. CONCLUSION: This survey offers insight into current expert opinion in the treatment of DED. The results of this survey are hypothesis generating and will aid in the design of future clinical studies. |
format | Online Article Text |
id | pubmed-4604775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46047752015-10-15 Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED) Sy, Aileen O’Brien, Kieran S. Liu, Margaret P. Cuddapah, Puja A. Acharya, Nisha R. Lietman, Thomas M. Rose-Nussbaumer, Jennifer BMC Ophthalmol Research Article BACKGROUND: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common treatments used among specialists and assess their interest in newer therapies. METHODS: An international survey was distributed to dry eye researchers and expert practitioners via an internet survey. The survey data collected were analyzed with descriptive statistics. RESULTS: One hundred and fifteen respondents completed the survey; of these, 66 % were cornea specialists. The most commonly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluorometholone (FML) 0.1 % (59/99, 60 %), loteprednol etabonate 0.5 % (50/99, 51 %), and autologous serum eye drops (ASD; 48/97, 49 %). The most commonly prescribed non-topical medications included essential fatty acid supplements (72/104, 69 %), low-dose doxycycline (oral; 61/100, 61 %), and flaxseed supplements (32/96, 33 %) as well as punctal plugs (76/102, 75 %). Respondents reported treatment with topical corticosteroids for 2 to 8 weeks (46/86, 53 %), followed by less than 2 weeks (24/86, 28 %) and with topical CSA between 2 to 8 weeks (45/85, 53 %) followed by 2 to 6 months (24/85, 28 %). The top three signs and symptoms reported to indicate treatment response were, in order, fluorescein staining of the cornea, reduction in foreign body sensation, and reduction in burning sensation. CONCLUSION: This survey offers insight into current expert opinion in the treatment of DED. The results of this survey are hypothesis generating and will aid in the design of future clinical studies. BioMed Central 2015-10-13 /pmc/articles/PMC4604775/ /pubmed/26462481 http://dx.doi.org/10.1186/s12886-015-0122-z Text en © Sy et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Sy, Aileen O’Brien, Kieran S. Liu, Margaret P. Cuddapah, Puja A. Acharya, Nisha R. Lietman, Thomas M. Rose-Nussbaumer, Jennifer Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED) |
title | Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED) |
title_full | Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED) |
title_fullStr | Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED) |
title_full_unstemmed | Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED) |
title_short | Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED) |
title_sort | expert opinion in the management of aqueous deficient dry eye disease (ded) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604775/ https://www.ncbi.nlm.nih.gov/pubmed/26462481 http://dx.doi.org/10.1186/s12886-015-0122-z |
work_keys_str_mv | AT syaileen expertopinioninthemanagementofaqueousdeficientdryeyediseaseded AT obrienkierans expertopinioninthemanagementofaqueousdeficientdryeyediseaseded AT liumargaretp expertopinioninthemanagementofaqueousdeficientdryeyediseaseded AT cuddapahpujaa expertopinioninthemanagementofaqueousdeficientdryeyediseaseded AT acharyanishar expertopinioninthemanagementofaqueousdeficientdryeyediseaseded AT lietmanthomasm expertopinioninthemanagementofaqueousdeficientdryeyediseaseded AT rosenussbaumerjennifer expertopinioninthemanagementofaqueousdeficientdryeyediseaseded |